Thursday, October 29, 2015

Alnylam to Report New RNAi Clinical Results in Transthyretin-Mediated Amyloidosis

Alnylam Pharmaceuticals (NASDAQ: ALNY) to Report New Clinical Results with Investigational RNAi Therapeutics for the Treatment of Transthyretin-Mediated Amyloidosis at the First European Congress on Hereditary ATTR Amyloidosis

Company to Present New Data from Phase 2 Open-Label Extension (OLE) Studies with Patisiran and Revusiran

The Conference Call on Tuesday, November 3, at 7:00 a.m. ET has been added to the Binary Event Calendar.

Here's the release.

No comments:

Post a Comment